The company behind the Covid-19 vaccine, AstraZeneca, is set to create 100 jobs in a new Dublin plant.
The biopharmaceutical manufacturer will build an advanced facility in Blanchardstown at a cost of over €300 million.
It is expected to create about 100 highly skilled direct jobs, including scientists and engineers.
The company will bring a significant investment to Dublin with the support of the IDA to nurture the country's dynamic life sciences sector and allow for the development of high value-added medicines.
They will establish a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules at the Alexion Campus in College Park.
Taoiseach Micheál Martin welcomed today's announcement from AstraZeneca that it is to establish its first ever manufacturing facility in Ireland.
He said: "In choosing Ireland as the location for its new next-generation active pharmaceutical ingredient manufacturing facility, AstraZeneca joins the very strong and successful network of global life sciences companies we have in Ireland.”
Tánaiste Leo Varadkar said that Ireland is a world hub for life sciences.
"We've worked hard to create a welcoming environment for companies seeking to invest here and we are so happy that AstraZeneca has chosen Dublin to locate its new manufacturing facility with 100 new jobs in the IDA College Park campus in Blanchardstown as a result," he added.
And IDA Ireland CEO Martin Shanahan said it was great to see AstraZeneca establish its first manufacturing facility in Ireland, adding that the new plant will be a considerable addition to the well established life sciences ecosystem here.
"Competition for Foreign Direct Investment (FDI) is more intense than ever and all investment is hard won. This investment, creating 100 highly skilled jobs, including scientists and engineers, is most welcome and will be of substantial benefit to the local economy," he concluded.
To get all the latest breaking headlines straight to your inbox sign up for our free newsletter
